医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Amway in Association With Kony Hosted First-Ever Hackathon to Advance Digital Transformation in the Industry
Amway India, the country’s no.1 direct selling fast-moving consumer goods (FMCG) company and Kony Inc., the leading provider of digital application and low-code platform solutions jointly hosted the first-ever hackathon for the students of Vasavi College of Engineering, Hyderabad. With an aim to harness the creativity of students to promote digital innovations and provide hands-on application development experience, the three-days long hackathon started from July 19, 2018 and ended on July 21, 2018.… 続きを読む
2018年07月21日 PM12:00
2018年07月20日
22ndセンチュリーはFDAのニコチン低減計画が直ちに実行可能であると発表
タバコの有害性低減と超低ニコチンタバコでリードする植物バイオテクノロジー企業の22ndセンチュリー・グループ(NYSE American:XXII)は昨日、米国で販売されるあらゆる紙巻きたばこのニコチン含有量を中毒性が最低かないレベルに抑えることを要求する規則を策定するための米国食品医薬品局(FDA)による制定規制案先行公示(ANPRM)に応答しました。当社の応答をFDAがオンラインでwww.regulations.govに掲載する際の対応トラッキングナンバーは1k2-94b8-wdcpとなります。FDAのANPRMに対する22ndセンチュリーの完全な応答は現在、www.xxiicentury.com/ANPRMでご覧いただけます。… 続きを読む
2018年07月20日
Emmaus Life Sciences宣布《新英格兰医学杂志》发表 Endari™(左旋谷氨酰胺口服粉剂)治疗镰状细胞病3期试验结果
参阅电子媒体包 – Emmaus Life Sciences, Inc. (Emmaus)今天宣布,《新英格兰医学杂志》(NEJM)已发表该公司Endari™(左旋谷氨酰胺口服粉剂)48周3期临床试验的结果,2017年7月,FDA依据该试验核准Endari™用于减少成人和5岁及以上儿童镰状细胞病患者的急性并发症。… 続きを読む
2018年07月20日
Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase (GSNOR) Assets to Laurel Venture Capital
Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer, autoimmune/inflammatory, and other diseases, and Laurel Venture Capital, a life science focused venture capital fund based in Hangzhou, Zhejiang China, today announced the completion of the sale and transfer of global rights to the S-Nitrosoglutathione Reductase (GSNOR) assets from Alpine to Laurel Venture Capital. The assets include broad intellectual property around small molecule GSNOR inhibitors, including the most clinically advanced orally active GSNOR inhibitor, cavosonstat, a product candidate for severe asthma and COPD demonstrating compelling safety and efficacy in preclinical and clinical studies. As a result of the transaction, Alpine will receive an upfront payment and is eligible for potential approval milestone and royalty payments. Alpine acquired the GSNOR assets as part of its merger with Nivalis Therapeutics, Inc. in 2017.… 続きを読む
2018年07月20日
Dr. Reddy’s Announces the Launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg in the U.S. Market
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, an over-the-counter (OTC) therapeutic equivalent generic version of Nexium® 24HR Capsules in the United States market as approved by the U.S. Food and Drug Administration (USFDA).… 続きを読む